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Abstract
Background: Initial success of inhibitors targeting oncogenes is often followed by tumor relapse due to acquired
resistance. In addition to mutations in targeted oncogenes, signaling cross-talks among pathways play a vital role in
such drug inefficacy. These include activation of compensatory pathways and altered activities of key effectors in
other cell survival and growth-associated pathways.
Results: We propose a computational framework using Bayesian modeling to systematically characterize potential
cross-talks among breast cancer signaling pathways. We employed a fully Bayesian approach known as the p1-model
to infer posterior probabilities of gene-pairs in networks derived from the gene expression datasets of ErbB2-positive
breast cancer cell-lines (parental, lapatinib-sensitive cell-line SKBR3 and the lapatinib-resistant cell-line SKBR3-R,
derived from SKBR3). Using this computational framework, we searched for cross-talks between EGFR/ErbB and other
signaling pathways from Reactome, KEGG and WikiPathway databases that contribute to lapatinib resistance. We
identified 104, 188 and 299 gene-pairs as putative drug-resistant cross-talks, respectively, each comprised of a gene in
the EGFR/ErbB signaling pathway and a gene from another signaling pathway, that appear to be interacting in
resistant cells but not in parental cells. In 168 of these (distinct) gene-pairs, both of the interacting partners are
up-regulated in resistant conditions relative to parental conditions. These gene-pairs are prime candidates for novel
cross-talks contributing to lapatinib resistance. They associate EGFR/ErbB signaling with six other signaling pathways:
Notch, Wnt, GPCR, hedgehog, insulin receptor/IGF1R and TGF-β receptor signaling. We conducted a literature survey
to validate these cross-talks, and found evidence supporting a role for many of them in contributing to drug resistance.
We also analyzed an independent study of lapatinib resistance in the BT474 breast cancer cell-line and found the
same signaling pathways making cross-talks with the EGFR/ErbB signaling pathway as in the primary dataset.
Conclusions: Our results indicate that the activation of compensatory pathways can potentially cause up-regulation
of EGFR/ErbB pathway genes (counteracting the inhibiting effect of lapatinib) via signaling cross-talk. Thus, the
up-regulated members of these compensatory pathways along with the members of the EGFR/ErbB signaling
pathway are interesting as potential targets for designing novel anti-cancer therapeutics.
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Background
Cancer development involves a series of events, rang-
ing from tumorigenesis to metastasis, each of which may
be caused by perturbations in crucial signal transduction
pathways. Recently, drugs (inhibitors) specifically target-
ing critical components of signaling pathways known to
be up-regulated in specific cancers have been used in the
clinic. However, success of these inhibitors is limited by
the intrinsic potential of cancer cells to acquire drug resis-
tance. Recent advances in both clinical and laboratory
research have reported that cancer cells may adopt sev-
eral mechanisms against particular treatments including
adjusting the signaling circuitry, activation of alterna-
tive pathways and cross-talks among various pathways to
overcome the effects of inhibitors [1,2]. Resistance to a
particular drug such as EGFR (Epidermal Growth Factor
Receptor) tyrosine kinase inhibitors, may occur not only
due to cross-talks among EGFR-mediated pathways, but
also due to cross-talks with pathways triggered by other
receptors. Therefore, targeting signaling cross-talks may
have the potential to sensitize cancer cells to particular
inhibitors.
Drug resistance is a major obstacle in drug efficacy that
causes cancer cells to be insensitive to targeted inhibitor
therapies and/or conventional chemotherapeutic agents
[1,2]. However, there are two categories of resistance to
inhibitor therapies: de novo and acquired [3]. By defi-
nition, de novo resistance is a phenotypic characteristic
present before drug exposure where drugs with proven
efficacy fail to cause tumor cells to respond with any sig-
nificance [2,4,5]. Acquired resistance refers to a situation
where the initial sensitivity of tumor cells to drugs dis-
continues despite or due to continued consumption [2].
It has been reported that the underlying mechanisms of
both types of resistance are related, often due to mutation,
loss, or up-regulation of some other important signaling
proteins or pathways [2,5]. De novo drug resistance can
be determined by assessing the genetic profiles of tumors
for 1) oncogenic addictions to proteins or pathways and
2) other possible genetic alterations conferring resistance
[2]. Therefore, targeting de novo resistance can enhance
drug efficacy and reduce the chance of acquired resistance
[5]. Recently, characterizing drug-resistant tumors, and
analyzing cell lines that result from the continuous culture
of drug-sensitive cells in the presence of an inhibitor have
been shown to be successful approaches for identifying
changes responsible for acquired resistance [2].
Cross-talk among signaling pathways may play a vital
role in cancer drug resistance, especially in receptor tar-
geted therapies. For example, in EGFR/HER2 signaling
pathways, cross-talk with other signaling pathways may
occur at various levels of signal transduction: recep-
tor level, mediator level and effector level [1]. At the
receptor level, other RTKs (receptor tyrosine kinases)
having common downstream targets of EGFR/HER2 may
become involved in cross-talk with EGFR/HER2 signal-
ing pathways. In many cancers, these alternative RTKs
including MET, IGF1R, FGFR and EphA2 become acti-
vated or amplified in order to maintain the signals
for cell survival and/or proliferation in common down-
stream pathways, thus nullifying the inhibition of EGFR
kinase [6-10]. Cross-talk at mediator level includes the
activation/inactivation of major components of media-
tor pathways by mutation/deletion of oncogenic driver
genes, which eventually activates downstream effectors
[1]. These constitutive activations/inactivations of medi-
ator pathways are independent of receptors. The effect
of signaling cross-talk in drug resistance at effector level
is more complex and diverse since there may be numer-
ous effectors of RTKs signaling pathways. Resistance at
the effector level may occur when some critical effectors
(i.e. TSC, FOXO3) involved in cell survival and prolifera-
tion show an altered phenotype caused by other signaling
pathways via RTK signaling cross-talk [1]. Additionally,
inhibitor sensitivity can be affected by cross-talk between
signaling pathways triggered by the targeted RTK and
other signaling pathways (triggered by other RTKs). For
example, the EGFR/HER2 signaling pathway can cross-
talk with Wnt/β-catenin, Notch, and TNFα/IKK/NF-κB
signaling pathways to affect the EGFR/HER2 inhibitors’
sensitivities [1]. Cross-talk between effector pathways and
feedback inhibition is also responsible for the adaptive
and dynamic response of cancer cells against inhibitor
therapies, for example, compensating the inhibited com-
ponents to maintain key downstream functions, such as
cell survival, proliferation etc. [11].
Lapatinib is a dual tyrosine kinase inhibitor of EGFR and
ErbB2/HER2 receptors [12] that is used in combination
therapy of ErbB2/HER2-positive breast cancer patients
with advanced or metastatic tumors [13]. Several studies
have examined the mechanism underlying lapatinib resis-
tance at themolecular [14-16] and system level [17], active
in HER2-positive breast cancer cell-lines through signal-
ing pathways. Garrett et al. [14] reported over-expression
ofHER2 orHER3 in lapatinib-resistant SKBR3 and BT474
breast cancer cell lines. Over-expression of AXL tyrosine
kinase was found in the BT474 cell-line [16], but interest-
ingly a switched addiction from HER2 to FGFR2 pathway
caused the UACC812/LR cell-line to become resistant to
lapatinib [15]. Moreover, a detailed analysis of the global
cellular network by Komurov et al. [17] revealed that
up-regulation of the glucose deprivation response path-
way compensates for the lapatinib inhibition in SKBR3
cell-line by providing an EGFR/ErbB2-independent mech-
anism of glucose uptake and survival [17]. Thus, the
activation or up-regulation of compensatory pathways
confers poor sensitivity of inhibitors (i.e. lapatinib resis-
tance) in EGFR or ErbB2 targeted therapy [1,2,17]. The
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identification and analyses of potential cross-talks among
the signaling pathways may provide deeper insights into
the mechanism of drug resistance, and can facilitate find-
ing a range of compensatory pathways for overcoming
resistance in targeted therapy.
In this study, we collected the gene expression val-
ues of the ErbB2-positive parental SKBR3 cell-line and
the lapatinib-resistant SKBR3-R cell-line, derived from
it, in the presence and absence of lapatinib [17]. Then
we used a fully Bayesian statistical modeling approach to
identify and analyze characteristic drug-resistant cross-
talks between EGFR/ErbB and other signaling pathways.
ln that process, we considered two gene-gene networks
originating from the gene expression matrices of both
parental and resistant conditions, individually. To say a
gene-pair involved in cross-talk between two particular
signaling pathways has high potential of being involved
in acquired drug-resistance, our research hypothesis was
it should have high probability of appearing in the resis-
tant network and low probability in the parental network.
The rationale behind our hypothesis was that in breast
cancer cell lines resistant to tamoxifen, a cross-talk mech-
anism has previously been identified between EGFR and
the IGF1R signaling pathway [18]. The schematic dia-
gram of our proposed framework is shown in Figure 1.
Like other biological processes, cancer signaling pathway
activities and their corresponding network data possess
stochasticity such that some gene-gene relationships (i.e.
network edges) may not always be present or detected,
whereas some other typical relationships may be absent.
The stochastic nature of biological systems can be used
to predict edge probabilities by formalizing them into a
probabilistic model with other network properties [19].
Hill et al. reported a data-driven approach that exploits a
Dynamic Bayesian Network (DBN) model to infer prob-
abilistic relationships between node-pairs in a context-
specific signaling network [20]. This study incorporates
existing signaling biology using an informative prior dis-
tribution on the network, and its weight of contribution
is measured with an empirical Bayes analysis, maximum
marginal likelihood. This study predicts a number of
known and unexpected signaling links through time that
are validated using independent targeted inhibition exper-
iments [20]. Here we have used a fully Bayesian approach
for inferring a probabilistic model: a special class of Expo-
nential Random Graph Model, namely the p1-model. We
used Gibbs sampling for estimating model parameters
with non-informative priors, in order to estimate the
posterior probabilities of edges in gene-gene relationship
networks. These identified cross-talks do not appear in
the parental network but only in the resistant one, because
the signaling network can be ‘rewired’ in a specific con-
text [21,22]. This idea resembles the approach taken by
Hill et al. in that they inferred the probabilities of signaling
links (gene-pairs) varying through time. Thus, these drug-
resistance cross-talks can be informative to elucidate the
complex mechanisms underlying drug-insensitivity and




A global gene expression (GE) dataset (GSE38376) from
1) cells sensitive to lapatinib (said to be under "parental
conditions") and 2) cells with acquired resistance to lapa-
tinib was obtained from Komurov et al. [17]. Expression
values were measured using Illumina HumanHT-12 V3.0
expression beadchip (GPL6947). Samples include SKBR3
parental and resistant (SKBR3-R) each under basal condi-
tions and in response to 0.1 μM and 1 μM lapatinib after
24 hours, where the resistant cell line variant (SKBR3-R)
showed 100-fold more resistance to lapatinib treatment
than the parental SKBR3 cell line, as reported by Komurov
et al. [17]. These gene expression datasets used probe-
level annotation, which we converted into gene-level
annotation. To obtain gene-level GE values, probes were
mapped to gene symbols using the corresponding anno-
tation file (GPL6947). While mapping, the average GE
values were calculated across all probes if the same
gene symbol was annotated to multiple probes. Two GE
data matrices were constructed for parental SKBR3 cell
lines and resistant SKBR3-R cell lines, respectively, where
rows were labelled with gene symbols and columns were
labelled with different treatment conditions (0, 0.1 μM
and 1 μM of lapatinib).
Construction of a gene-gene relationship network
We define the gene-gene relationship network as GGR:=
(S,R) for each GE data matrix. Here, S is a set of 370 can-
cer related genes collected from the Cancer Gene Census
[23]. R is defined as the set of pair-wise relationships
among seed genes. A gene pair (genei, genej) is included
in R if the corresponding absolute Pearson Correlation
Coefficient (PCC) is above some threshold, and defined
as a pair-wise relationship. These threshold values were
empirically chosen for parental and resistant conditions
individually, based on the corresponding distributions of
all pairwise absolute PCC values. Note PCC values result-
ing from probes mapped to the same gene were trivially
ignored.
Bayesian statistical modeling ofGGR network
Networkmodel
For statistical modeling of networks, exponential fami-
lies of distributions offer robust and flexible parametric
models [24]. These probabilistic models can be used to
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Figure 1 Schematic diagram of our proposed framework. (A) The framework for finding putative drug-resistant cross-talks. At first two gene
expression data matrices were generated individually from the samples of both parental and resistant conditions. Next, based on pair-wise
correlations of genes’ expression values, two gene-gene relationship networks were derived. Then, a Bayesian statistical model called the p1-model
was applied on those two networks to find posterior probabilities of network edges. These posterior probabilities were used to find gene-pairs
potentially contributing to drug resistance. Next, these gene-pairs were analyzed for overlap with cross-talks between EGFR/ErbB and other
signaling pathways, and thus putative drug-resistant cross-talks were identified. (B) Hierarchical Bayesian model for inferring posterior probabilities
of network parameters. Here, α represents the propensity (expansiveness/attractiveness) of a gene to be connected in an undirected network, and




is the scaling parameter, which is fixed due to the
constraint
∑
k Yijk = 1; the hyperparameter τθ represents precision of the normal prior for the parameter θ .
evaluate the probability that an edge is present in the
network. They can also be used to quantify topological
properties of networks by summarizing them in a para-
metric form and associating sufficient statistics with those
parameters [19,24]. In this study, we use a special class of
exponential family distributions known as ERGM (Expo-
nential Random Graph Models), also known as the p1-
model, which was introduced by Holland and Leinhardt
[24].
A gene-gene relationship network with g genes can
be regarded as a random variable X taking values from
a set G containing all 2g(g−1) possible relationship net-
works [24,25]. Let u be a generic point of G which can
alternatively be denoted as the realization of X by X =
u. Let the binary outcome uij = 1 if genei interacts with
genej, or uij = 0 otherwise. Then u is a binary data
matrix [19]. Let Pr(u) be the probability function on G
given by
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where zp(u) is the network statistic of type p, θp is the
parameter associated with zp(u) and κ(θ) is the normal-
izing constant that ensures Pr(u) is a proper probability
distribution (sums to 1 over all u inG) [26]. The parameter
θ is a vector of model parameters associated with network
statistics and needs to be estimated. See [24] for further
details.
A major limitation of the p1-model is the difficulty of
calculating the normalizing constant, κ(θ), since it is a
sum over the entire graph space. Estimating the maximum
likelihood of this model becomes intractable as there
are 2g(g−1) possible directed graphs (or 2
g(g−1)
2 undirected
graphs), each having g nodes (genes). A technique called
maximum pseudolikelihood estimation has been devel-
oped to address this problem [27]. This technique employs
MCMC methods such as Gibbs or Metropolis-Hastings
sampling algorithms [28].
The construction of the p1-model for a directed network
is described in an Appendix Additional file 1: Appendix
I. For the gene-gene relationship network with undirected
edges, the description of the p1-model can be simplified
by using only two Bernoulli variables Yij0 and Yij1 instead
of four as follows:
Yijk =
{
1 if uij = k,
0 otherwise
The simplified p1-model can then be defined using the
following two equations to predict the probability of an












)} = λij (3)







) = 1. In this formulation, the expansiveness
and attractiveness parameters were reduced to a single
parameter, α, which represents the propensity of a gene
to be connected in an undirected network. Hence, the p1-
model seeks to find the probabilities of edge formation in
a network considering its structural features explicitly.
Bayesian modeling
We used a fully Bayesian approach for modeling our
gene-gene relationship network. Parameter estimation is
a crucial step in statistical modeling, for which a classical
approach is maximum likelihood estimation (MLE). How-
ever, unlike MLE, Bayesian techniques involve calculation
of posterior probabilities of model parameters by train-
ing the model with given data. We assume that the data D
follows the generative modelM, and assign a prior proba-
bility P (θ |M) to the parameter vector θ under the model
M. Then Bayes’ rule for calculating posterior probability
is as follows:
Pr (θ |M,D) = Pr (D|θ ,M) × Pr (θ |M)Z (4)
where Pr (D|θ ,M) is the likelihood function. Now, the
marginal likelihood Z can be expressed as
Z = Pr (D|M) =
∫
Pr (D|M, θ) × P (θ |M)dθ , (5)
Computing the exact solution for the marginal likeli-
hood Z is often intractable since it is prone to the curse
of dimensionality. Fortunately, Markov Chain Monte
Carlo (MCMC) methods such as Gibbs sampling and
Metropolis-Hastings methods do not require Z to be
explicitly computed. In general, MCMC methods are
stochastic simulation techniques which generate samples
from the joint distribution P (M, θ |D) for calculating the
posterior probabilities of parameters. Here we used Gibbs
sampling methods, which sample iteratively, one parame-
ter at a time, from the full conditional distribution given
the current and previous values of all other parameters. To
implement Gibbs sampling, we employed WinBUGS [29],
which is a high-level software package providing an easy
interface for implementing complex Bayesian models. In
WinBUGS, users are free from background lower-level
programming details, and only have to express the model
precisely.
We hypothesized that gene-pairs involved in drug resis-
tance are likely to be found with high probabilities in
the resistant network but low probabilities in the parental
network. Therefore, we built two networks, one from
resistant datasets and the other from parental datasets. In
this Bayesian approach, the model likelihood is defined
in Equations (2) and (3), where Yk is the data matrix cal-
culated from the observed data u. Here we have two Yk
data matrices, namely a gene-gene relationship network
YkR derived from resistant samples and YkP derived from
parental samples.
Our approach is a hierarchical Bayesian model in that
model parameters are in turn dependent on hyperparam-
eters. We assign the density parameter θ in Equation (2)
a normal prior distribution with mean 0 and standard
deviation σθ .
θ ∼ N (0, σθ 2) (6)
Note, inWinBUGS the parameter τ , called the precision,
replaces the standard deviation parameter σ of the normal
distribution, where, τ = σ−2. For the hyperparameter τθ
we specify a gamma prior distribution as follows, since it
is a conjugate prior for the normal distribution:
τθ ∼ Gamma (a0, b0) (7)
We set a0 = 0.001 and b0 = 0.001 to make the
prior for θ noninformative, making its standard deviation
wide to express large uncertainty [19]. For attractiveness/
Azad et al. BMC Systems Biology  (2015) 9:2 Page 6 of 17
expansiveness parameters αi and αj, we followed the




















Here, αRi and αPi represent the expansiveness/
attractiveness parameters for the network model of
resistant and parental conditions, respectively.
Drug resistant cross-talk prediction
Since, Lapatinib is an EGFR and ErbB inhibitor, we con-
sidered the cross-talks between the EGFR/ErbB signaling
pathway and other signaling pathways. Here cross-talks
can be defined as any gene-pair (genei, genej) in which
genei ∈ {genes in EGFR/ErbB signaling pathway} and
genej ∈ {genes in other signaling pathways}, or vice versa
[31]. Thus if both genes in any gene-pair were found
in the same signaling pathway, that particular gene-pair
was trivially ignored. For that purpose, we collected 24
signaling pathways from Reactome [32] (downloaded at
19/05/2014), 35 signaling pathways from KEGG [33,34]
(downloaded at 21/10/2014), and 63 signaling path-
ways fromWikiPathway [35] (downloaded at 16/10/2014)
databases. Each signaling pathway downloaded from these
databases was encoded as tab-delimitated lists of gene
symbols.
To determine whether a given gene-pair is involved in
drug resistance, we calculated a simple odds ratio of the










where, YRij1 and YPij1 are gene-gene relationships defined
over resistant and parental networks, respectively, and
the probabilities are estimated using MCMC sampling.
We then selected only those gene-pairs for which the




are greater than conservative
thresholds, and identified these as the gene-pairs which
are potentially involved in drug-resistance.
Results
Developing the network
For building gene-gene relationship networks, we con-
sidered the genes (nodes) from the Cancer Gene Census
[23] only, since our aim was to find those gene-gene
relationships which could be potential cross-talks among
cancer signaling pathways. In order to identify such gene-
pairs, we applied thresholds on their absolute Pearson
Correlation Coefficient (PCC) values. These thresholds
were 0.545 and 0.54 for parental and resistant conditions,
respectively, which we selected from the corresponding
distributions of all-pair absolute PCC values with the pur-
pose of considering approximately the top 20% gene-pairs
as pairwise relationships only. Applying these thresholds
to the relationship values, 27,865 and 26,865 pair-wise
relationships were identified in parental and resistant data
matrices, respectively.
Bayesian analysis
For the two gene-gene relationship networks YkR and YkP ,
Bayesian inference of the parameters of the p1-model for
an undirected network was applied. We used WinBUGS
for scripting this inference and our scripts were inspired
by Adams et al. [30]. We used 6000 MCMC iterations
for parameter estimation with the first 5000 as ‘burn-in’.
All the parameters in the p1-model appeared to converge
rapidly during the burn-in iterations (data not shown).
With the above settings, we estimated the posterior proba-




in the two networks YkR and YkP. For each edge, the pro-
portion of the 1000 sampled networks containing the edge
was considered as the posterior probability of that edge
being present in the network.
Next, for each edge we calculated the odds ratio of their
posterior probabilities as defined above. The rationale
behind this calculation was that the edges (gene-pairs)
found with high probabilities in resistant conditions but
lower probabilities in parental conditions are more likely
to be due to acquired resistance in cell lines. Therefore,
we chose only gene-pairs with high odds ratio (≥ 10.0)
and high posterior probabilities (≥ 0.5) of occurring in
resistant conditions. We found 11,515 such gene-pairs
(Additional file 2: Table S1) among all 68,265 [= (370 ×
369) ÷ 2] possibilities.
We then observed whether the above gene-pairs overlap
with the list of potential cross-talks between EGFR/ErbB
signaling and other signaling pathways. Here, we collected
24 signaling pathways from Reactome [32], 35 signaling
pathways from KEGG [33,34], and 63 signaling path-
ways from WikiPathway [35] databases, and respectively
identified 1,083 (841 distinct), 2,179 (1,050 distinct) and
3,084 (876 distinct) gene-pairs (Additional file 3: Table S2,
Additional file 4: Table S3 and Additional file 5: Table S4)
between EGFR/ErbB and other signaling pathways (see
Materials and method). Of the 11,515 gene-pairs identi-
fied above, we found 104 (97 distinct), 188 (99 distinct)
and 299 (96 distinct) gene-pairs overlap with the potential
EGFR cross-talks identified using Reactome, KEGG and
WikiPathway, respectively. Note the number of potential
cross-talks and the number of distinct gene-pairs are dif-
ferent because the same gene-pair can form cross-talks
between multiple pathway-pairs (pathways are overlap-
ping). We consider these overlapping gene-pairs as puta-
tive drug-resistant cross-talks between EGFR/ErbB and
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other signaling pathways. In these 104, 188 and 299 cross-
talks, we found candidate EGFR/ErbB cross-talks with 13,
26 and 51 other signaling pathways, respectively. More-
over, among all 104, 188 and 299 cross-talks from Reac-
tome, KEGG and WikiPathway, respectively, we found 32
distinct gene-pairs in at least two of these sets. Primary
findings and detailed descriptions of all these putative
cross-talks from the analyses of all three pathway sources
are listed in Table 1, and Additional file 6: Table S5,
Additional file 7: Table S6 and Additional file 8: Table S7,
respectively. The network views of all these cross-talk sets
from the analyses of individual pathway sources are shown
in Figure 2.
Netwalker analyses
We conducted further analyses using Netwalker, a net-
work analysis suite for functional genomics [36]. In this
analysis, we observed the changes in GE values for each
gene in the identified list of potential cross-talks. This
was to verify our expectation that, since lapatinib is
an EGFR/ErbB inhibitor, both genes involved in drug-
resistant cross-talks should be up-regulated in resistant
conditions compared to parental conditions, which may
imply that the activation of other compensatory signal-
ing pathways in resistant conditions can play a role in
acquired resistance to inhibitors by activating the targeted
pathway(s) [1,17]. Therefore, for all 67 genes involved in
the above sets of 104, 188 and 299 drug-resistant cross-
talks from Reactome, KEGG and WikiPathway, respec-
tively, we made a heatmap image of GE values from both
conditions (parental and resistant) (Figure 3A). For both
resistant and parental conditions, we first averaged the
gene expression values from the three samples corre-
sponding to the three treatment conditions. Then these
averaged gene expression values were transformed into
z-scores (zero mean, unit standard deviation) and each
z-score was normalized with the maximum of the abso-
lute values of the z-scores across that particular gene.
We observed that in 28 of these 67 genes (involved in
168 cross-talks), gene expression in one or more resis-
tant conditions (0, 0.1 μM and 1 μM of lapatinib) was
up-regulated relative to all the parental conditions (0, 0.1
μM and 1 μM of lapatinib) (Figure 3B) which may signify
the insensitivity of these genes to inhibitors under resis-
tant conditions. Note for Figure 3B only those genes are
depicted for which both genes in some identified cross-
talk had average GE values at resistant conditions greater
than the average GE values at parental conditions.
For these 28 selected genes (168 cross-talks), we
observed the relative changes in GE values (parental vs
resistant conditions) in their candidate signaling path-
ways. First we analyzed EGFR signaling pathway from
Reactome and found that many of the constituent genes
were up-regulated in one (or more) resistant conditions
whereas in all of their corresponding parental conditions
they were down-regulated (Additional file 1: Figure S1).
These 168 selected cross-talks associated EGFR (or ErbB)
signaling pathways with 6 other signaling pathways that
were found in at least two different pathway analyses
(i.e. Reactome and KEGG, or KEGG and WikiPathway,
or Reactome and WikiPathway). In those 6 other signal-
ing pathways, we also observed a similar phenomenon
as above (Additional file 1: Figure S1). These 6 signaling
pathways are Notch signaling (in Reactome, KEGG and
WikiPathway), Wnt signaling (in Reactome, KEGG and
WikiPathway), insulin receptor/IGF1R signaling (in Reac-
tome and WikiPathway), GPCR signaling (in Reactome
and WikiPathway), hedgehog (in KEGG and WikiPath-
way), and TGF-β receptor signaling (in Reactome and
WikiPathway). Again, for many of the constituent genes of
these 6 signaling pathways, expression was up-regulated
in at least one of the resistant conditions whereas in all
the corresponding parental conditions they were down-
regulated. Primary findings regarding these 168 selected
drug-resistant cross-talks are listed in Additional file 9:
Table S8, and the top 50 of those 168 cross-talks (based on
sorted Odds ratio) are shown in Table 2.
Signaling cross-talk between EGFR/ErbB and other
signaling pathways
Cross-talk between EGFR/ErbB and Notch signaling
We investigated literature evidence regarding the putative
cross-talks between EGFR/ErbB signaling and other sig-
naling pathways. We found AKT2:MAML2 (in Reactome
Table 1 Primary findings from the analyses using signaling pathways from Reactome, KEGG andWikiPathway in breast
cancer cell-line: SKBR3 (GSE38376)
Pathway # of signaling Pathway of All Distinct All putative Distinct # of other
source pathways interest Cross-talks gene-pairs§ drug-resistant gene-pairs¶ signaling
of interest cross-talks pathways
REACTOME 23 EGFR 1,083 841 104 97 13
KEGG 35 ErbB 2,179 1,050 188 99 26
WikiPathway 63 ErbB 3,084 876 299 96 51
¶Number of distinct gene-pairs involved in all EGFR/ErbB cross-talks with all other signaling pathways; §Number of distinct gene-pairs commonly involved in all
EGFR/ErbB cross-talks and drug resistance.
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Figure 2 Network view of (A) 104, (B) 188, and (C) 299 putative drug-resistant cross-talks between pathways using Reactome, KEGG, and
WikiPathway pathway databases in Breast Cancer Cell-line: SKBR3 (GSE38376). Nodes are genes, and the edges are the cross-talks. Note, all
the cross-talks here possess posterior probabilities of appearing in resistant network ≥ 0.5 and Odds Ratio ≥ 10.0, which means the posterior
probabilities of that cross-talk for appearing in parental network is ≤ 0.05.
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Figure 3 Heatmap of genes in putative drug-resistant cross-talks in breast cancer cell-line: SKBR3 (GSE38376). Heatmap image of
comparative gene expression changes of parental and resistant conditions in (A) all 67 genes in all 104, 188 and 299 putative drug-resistant cross-
talks using signaling pathways from Reactome, KEGG and WikiPathway database, respectively, and (B) 28 selected genes based on their differential
regulation. Here, for each gene, the expression value at each of the 6 conditions (3 parental conditions, and 3 resistant conditions) is the average
value of 3 sample patients [17]. For each gene, these 6 expression values (each of them is the average of 3 samples) were transformed into z-scores
(zero mean, unit standard deviation) and each z-score was normalized with the maximum absolute value of the z-scores across that particular gene.
Note, (B) includes only those genes which belonged to gene-pairs for which the average of GE values at resistant conditions was greater than the
average of GE values at parental conditions. For both (A) and (B), red and green bars indicate up-regulation and down-regulation, respectively.
and KEGG), AKT2:TP53 (in Reactome), AKT2:MYC (in
Reactome), KIT :MAML2 (in Reactome), KIT :TP53 (in
Reactome),MDM2:MAML2 (in Reactome and WikiPath-
way),MDM2:TP53 (in Reactome), and TP53:MAML2 (in
WikiPathway) gene-pairs as putative cross-talks between
EGFR/ErbB signaling and Notch signaling pathways. Up-
regulation of the Notch signaling pathway inhibits apop-
tosis and thus contributes to breast carcinogenesis [37].
The Notch signaling pathway cross-talks with EGFR/ErbB
signaling at the mediator level [1], e.g. when activated,
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Notch1 contributes to cell growth and survival via Akt-
activation in melanoma [38]. The Notch1 co-activator
complex binds to the HES1 promoter [39] which encodes
a transcription repressor that represses the expression of
PTEN, a PI3K/Akt pathway inhibitor [40] contributing to
tyrosine kinase inhibitor (TKI) resistance. Furthermore,
Notch1 stimulates MYC transcription [41] and this stim-
ulation can lead to the down-regulation of MYC via the
Akt-pathway [42,43]. This putative gene-pair, AKT2:MYC
was also found in our results as a potential drug-resistant
cross-talk between the EGFR/ErbB and TGF-β receptor
signaling pathways. Again, in HER2/neu-mediated resis-
tance toDNA-damaging agents, theAkt pathway becomes
activated which eventually suppresses p53 functions via
enhancing MDM2-mediated ubiquitination [44]. Protein-
protein interaction between MDM2 and p53 is evident as
contributing to various cancer related activities [45,46].
Cross-talk between EGFR/ErbB andWnt signaling
We found MDM2:APC (in Reactome and WikiPath-
way), KIT :CDC73 (in Reactome), MDM2:CDC73
(in Reactome), CBL:APC (in Reactome and KEGG),
PDGFRA:APC (in Reactome), and CBL:CDC73 (in
Reactome), AKT2:APC (in KEGG), AKT2:TP53 (in
KEGG), and TP53:APC (in WikiPathway) as putative
drug-resistant cross-talks between EGFR/ErbB and Wnt
signaling pathways. Deregulation of the Wnt/β-catenin
signaling pathway plays a critical role in various cancers
including breast, colorectal, pancreatic and colon can-
cer [47,48], and its association with drug-resistance has
been studied by several research groups [47-50]. Recently,
it has been reported that resistant cell lines exhibited
increased Wnt signaling in both breast and colon cancer
[49,50]. Loh et al. showed that genes in the Wnt signaling
pathway, in both the β-catenin dependent (AXIN2, MYC,
CSNK1A1) and the independent arms (ROR2, JUN), were
up-regulated in cell lines resistant to tamoxifen com-
pared to the parental MCF7 cell line [49]. Furthermore,
ROR1, a constituent gene of Wnt signaling pathway,
plays a sustainer role in EGFR-mediated prosurvival sig-
naling in lung adenocarcinoma via signaling cross-talk
and was therefore reported to be a potential therapeu-
tic target [51]. APC and MDM2 in the MDM2:APC
cross-talk are both tumor suppressors; they co-regulate
DNA polymerase-β [52,53] which is reported to be
hyper-activated in a cis-diamminedichloroplatinum(II)
resistant P388 murine leukemia cell line [54]. Again,
β-catenin whose stability is negatively regulated by APC
[55], confers resistance to PI3K/Akt inhibitors in colon
cancer [56].
Cross-talk between EGFR/ErbB and GPCR signaling
Between EGFR/ErbB and GPCR signaling pathways,
we found KIT :GNAQ (in Reactome), MDM2:GNAQ (in
Reactome and WikiPathway), CBL:GNAQ (in Reactome),
FGFR2:GNAQ (in Reactome), PDGFRA:GNAQ (in Reac-
tome), KIT :TSHR (in Reactome), MDM2:TSHR (in Reac-
tome), CBL:TSHR (in Reactome), PDGFRA:TSHR (in
Reactome), KIT :GNAS (in Reactome), MDM2:GNAS (in
Reactome and WikiPathway), KIT :SMO (in Reactome),
MDM2:SMO (in Reactome), TP53:GNAQ (in WikiPath-
way), and MYC:GNAQ (in WikiPathway). GPCR-like sig-
naling contributes to acquired drug resistance after being
mediated by Smoothened (SMO) via activating Gli, a
canonical hedgehog (Hh) transcription factor [57]. GPCR
and EGFR/ErbB over-expression often contributes to can-
cer growth. Cross-talk between the two at the receptor
level contributes to HNSCC (head and neck squamous
cell carcinoma) via triggering EGFR/ErbB signaling by
a GPCR ligand [58]. For the MDM2:SMO cross-talk,
found between the EGFR/ErbB and GPCR signaling path-
ways, a SMO-mutant from Hh signal transducer activates
PI3K/Akt/Gli pathway that eventually increases MDM2
phosphorylation [59]. This in turn increases MDM2-
mediated p53 degradation and thus reduces p53-induced
apoptosis [59]. Furthermore, recently it has been reported
that SMO (Hh signal transducer) functions like a G-
protein coupled receptor due to its structural resemblance
to GPCRs [60,61] which may be further evidence for a
drug-resistant cross-talk between hedgehog signaling and
EGFR/ErbB signaling [1].
Cross-talk between EGFR/ErbB and IR (insulin
receptor)/IGF1Rsignaling
Several studies have reported extensive cross-talk
between IR (insulin receptor)/IGF1R (insulin-like growth
factor-1 receptor) and EGFR/ErbB signaling pathways
contributing to acquired drug resistance in various
cancers [62-64]. Loduvini et al. reported significant cor-
relation between worse disease-free survival and high
co-expression of both EGFR/ErbB and IGF1R in NSCLC
(non-small-cell lung cancer) patients [65]. EGFR/ErbB
can physically interact with other non-ErbB family recep-
tors at the cell surface and can form heterodimers with
receptors like IGF1R, PDGFR etc. [62]. Moreover, the
EGFR/ErbB and IGF1R pathways can also cross-talk indi-
rectly via physical interactions between their downstream
shared-components [62]. It has been reported recently
that gefitinib (an EGFR TKI) inhibits the phosphory-
lation of IRS1 by IR, but also triggers the association
between IRS1 and IGF1R which in turn induces drug-
resistance [66]. Knowlden et al. showed the cross-talk
between IGF1R and EGFR signaling pathways occurred
in tamoxifen-resistant MCF7 and T47D breast cancer
cell-lines but not in non-resistant cells [18]. Our find-
ings suggest KIT :STK11 (in Reactome), MDM2:STK11
(in Reactome), MDM2:AKT2 (in WikiPathway), MYC:
AKT2 (in WikiPathway), TP53:AKT2 (in WikiPathway),
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MDM2:CBL (in WikiPathway), MDM2:SOCS1 (in Wiki-
Pathway), and TP53:SOCS1 (in WikiPathway) as puta-
tive drug-resistant cross-talks between the IGF1R/IR
and EGFR/ErbB signaling pathways. For the MDM2 and
STK11 (also known as LKB1) genes, which we identified
as a putative cross-talk between EGFR and IGF1R sig-
naling, we did not find any direct supporting evidence in
the literature. However, this association is plausible in the
resistant conditions given that Yamaguchi et al. suggested
EGFR signaling may cross-talk with the AMPK/LKB
signaling pathway [1]. Moreover, Levine et al. reported
interconnections between p53 and IGF1R/AKT/mTOR
pathways where both LKB1 and MDM2 participate in a
series of pathway cross-talks [67].
Validation of the framework using BT474 cell-line
(GSE16179)
To further illustrate our method, we analysed a second
dataset (GSE16179) containing gene expression profiles
of breast cancer cell-line BT474 under two conditions
(parental and lapatinib resistant) [16]. The reason for
choosing this dataset was that it was obtained using
a similar experimental design to the primary dataset
GSE38376, but with an additional treatment condition
using foretinib (GSK1363089) only and with combined
drug use (lapatinib + foretinib). There were three sam-
ples per treatment condition. However, to adapt simply
and be coherent with the previous experiment, we only
considered expression values of parental conditions (3
samples with basal condition: GSM799168, GSM799169
and GSM799170; 3 samples with 1 μM of lapatinib treat-
ment: GSM79917, GSM799172 and GSM799173), and
the same conditions with lapatinib resistant cells (3 sam-
ples with basal condition: GSM799174, GSM799175 and
GSM799176; 3 samples with 1 μM of lapatinib treatment:
GSM799180, GSM799181 and GSM799182). Among the
375 cancer genes from Cancer Gene Census [23], there
were 357 genes which had gene expression values. We
identified 27,358 and 26,292 pair-wise gene-gene rela-
tionships (undirected edges) in resistant and parental
networks by applying the thresholds 0.71 and 0.81, respec-
tively. Bayesian inference of the p1-model parameters for
an undirected network was applied to these two gene-
gene relationship networks as before. Thereafter, among
all 63,546 [= (357×356)÷2] possibilities, we found 10,811
gene-pairs (Additional file 10: Table S9) with the same
thresholds of odds ratio (≥10.0) as previously, but smaller
posterior probability (≥0.15) of occurring in the resistant
network. With this set of putative drug-resistant gene-
pairs, we also observed the overlap of potential cross-talks
of EGFR/ErbB with other signaling pathways using Reac-
tome, KEGG and WikiPathway databases. We found 83
(72 distinct), 133 (87 distinct) and 277 (81 distinct) cross-
talks between EGFR/ErbB and other signaling pathways
from Reactome, KEGG and WikiPathway (Additional
file 11: Table S10, Additional file 12: Table S11 and Addi-
tional file 13: Table S12), respectively. The numbers of sig-
naling pathways that were involved in those EGFR/ErbB
cross-talks were 10, 18 and 54, respectively. Among the 83,
133 and 277 cross-talks, we found 50 distinct gene-pairs
in at least two of these sets. Table 3 shows the comparative
findings between our primary dataset (SKBR3 cell-line,
GSE38379) and our secondary dataset (BT474 cell-line,
GSE16179). In Table 3, we show that some important sig-
naling pathways that were involved in the EGFR/ErbB
cross-talks (i.e. Notch, WNT, GPCR, IR/IGF1R, TGF-β
signaling pathways) in our primary dataset, have some
overlap with our secondary dataset.
There were 78 genes involved in these sets of 83, 133
and 277 putative cross-talks.We performed a similar Net-
walker analyses with these 78 genes as we did for the
dataset GSE38376, and found 37 genes (involved in 86
cross-talks (Additional file 14: Table S13)) consistent with
our hypothesis that both genes in a particular cross-talk
should be up-regulated in resistant conditions but down-
regulated in parental conditions. In Figure 4, the selected
genes from the secondary dataset exhibit an even clearer
pattern of up-regulation in resistant conditions than the
selected genes from our primary dataset.
Discussion
In this study, we developed a computational framework
to systematically predict signaling cross-talks between
EGFR/ErbB and other signaling pathways that contribute
to lapatinib (an EGFR and ErbB2/HER2 inhibitor) resis-
tance. We hypothesized that gene-pairs (cross-talks) that
can potentially cause drug-resistance have a high proba-
bility of occurring in the resistant condition(s) but a low
probability in parental conditions. We employed a fully
Bayesian statistical model: a special class of Exponen-
tial Random Graph Model known as the p1-model, to
infer the posterior probabilities of such gene-pairs from
corresponding networks inferred using gene expression
values [17] of resistant and parental conditions. In select-
ing gene-pairs as putative cross-talks, threshold values for
two parameters: odds and posterior probabilities of edges
in resistant networks were empirically selected. How-
ever, more robust procedures for the selection of these
two parameters can be made in future studies. All other
parameters in the p1-model discussed above were esti-
mated using Gibbs sampling (see Materials and method).
Our results primarily focus on compensatory signal-
ing pathways i.e. Notch signaling, Wnt signaling, GPCR
signaling, and IR/IGF1R signaling, which cross-talk with
EGFR/ErbB signaling to reduce the inhibiting effect of lap-
atinib. We present additional literature evidence that the
identified cross-talks of the above compensatory signal-
ing pathways with EGFR/ErbB signaling may contribute
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Table 2 Description of top 50 (based on sorted Odds ratio) cross-talks among all 168 potential drug-resistant cross-talks
between EGFR/ErbB signaling and other pathways from all the analyses using Reactome, KEGG andWikiPathway
databases in GSE38376

























AKT2::MAML2§ ,¶ Notch signaling 0.5 0.03 16.67 87.71::76.59 96.84::78.6
MDM2::APC§ ,$ Wnt signaling 0.5 0.03 16.67 76.33::82.43 77.9::86.76
KIT::CDC73§ Wnt signaling 0.5 0.03 16.67 82.14::104.01 82.68::110.88
MDM2::CDC73§ Wnt signaling 0.5 0.03 16.67 76.33::104.01 77.9::110.88
KIT::GNAQ§ GPCR signaling 0.5 0.03 16.67 82.14::130 82.68::139.33
MDM2::GNAQ§ ,$ GPCR signaling 0.5 0.03 16.67 76.33::130 77.9::139.33
KIT::TSHR§ GPCR signaling 0.5 0.03 16.67 82.14::71.32 82.68::71.66
MDM2::TSHR§ GPCR signaling 0.5 0.03 16.67 76.33::71.32 77.9::71.66
AKT2::APC¶ Wnt signaling 0.5 0.03 16.67 87.71::82.43 96.84::86.76
AKT2::APC¶ Hippo signaling 0.5 0.03 16.67 87.71::82.43 96.84::86.76
AKT2::CDH1¶ Hippo signaling 0.5 0.03 16.67 87.71::74.2 96.84::79.8
AKT2::GNAQ¶ Gnrh signaling 0.5 0.03 16.67 87.71::130 96.84::139.33
AKT2::GNAQ¶ Calcium signaling 0.5 0.03 16.67 87.71::130 96.84::139.33
AKT2::MDM2¶ p53 signaling 0.5 0.03 16.67 87.71::76.33 96.84::77.9
MDM2::AKT2$ Regulation of toll-like 0.5 0.03 16.67 76.33::87.71 77.9::96.84
receptor signaling
MDM2::AKT2$ insulin signaling 0.5 0.03 16.67 76.33::87.71 77.9::96.84
MDM2::AKT2$ RANKL/RANK signaling 0.5 0.03 16.67 76.33::87.71 77.9::96.84
MDM2::AKT2$ AMPK signaling 0.5 0.03 16.67 76.33::87.71 77.9::96.84
MDM2::AKT2$ MAPK signaling 0.5 0.03 16.67 76.33::87.71 77.9::96.84
MDM2::AKT2$ Tweak signaling 0.5 0.03 16.67 76.33::87.71 77.9::96.84
MDM2::AKT2$ Toll-like 0.5 0.03 16.67 76.33::87.71 77.9::96.84
receptor signaling
MDM2::APC$ BDNF signaling 0.5 0.03 16.67 76.33::82.43 77.9::86.76
MDM2::APC$ Wnt signaling Netpath 0.5 0.03 16.67 76.33::82.43 77.9::86.76
MDM2::APC$ Wnt signaling 0.5 0.03 16.67 76.33::82.43 77.9::86.76
and Pluripotency
MDM2::COL1A1$ Nanoparticle-mediated 0.5 0.03 16.67 76.33::91.44 77.9::102.54
activation of receptor
signaling
MDM2::COL1A1$ Osteoblast signaling 0.5 0.03 16.67 76.33::91.44 77.9::102.54
MDM2::GNAQ$ TSH signaling 0.5 0.03 16.67 76.33::130 77.9::139.33
MDM2::GNAQ$ Serotonin Receptor 2 0.5 0.03 16.67 76.33::130 77.9::139.33
and STAT3 signaling
MDM2::GNAQ$ Serotonin Receptor 2 0.5 0.03 16.67 76.33::130 77.9::139.33
and ELK-SRF/GATA4
signaling
MDM2::ITK$ T-Cell Receptor and 0.5 0.03 16.67 76.33::89.86 77.9::93.27
Co-stimulatory signaling
MDM2::ITK$ Tcr signaling 0.5 0.03 16.67 76.33::89.86 77.9::93.27
MDM2::KIT$ Kit receptor signaling 0.5 0.03 16.67 76.33::82.14 77.9::82.68
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Table 2 Description of top 50 (based on sorted Odds ratio) cross-talks among all 168 potential drug-resistant cross-talks
between EGFR/ErbB signaling and other pathways from all the analyses using Reactome, KEGG andWikiPathway
databases in GSE38376 (Continued)
MDM2::PAX5$ ID signaling 0.5 0.03 16.67 76.33::68.91 77.9::71.02
MDM2::TSHR$ TSH signaling 0.5 0.03 16.67 76.33::71.32 77.9::71.66
AKT2::TP53§ Notch signaling 0.5 0.04 12.5 87.71::128.73 96.84::155.09
KIT::APC§ Wnt signaling 0.5 0.04 12.5 82.14::82.43 82.68::86.76
KIT::MAML2§ Notch signaling 0.5 0.04 12.5 82.14::76.59 82.68::78.6
KIT::STK11§ IGF1R signaling 0.5 0.04 12.5 82.14::71.97 82.68::74.95
KIT::STK11§ insulin receptor signaling 0.5 0.04 12.5 82.14::71.97 82.68::74.95
KIT::TP53§ Notch signaling 0.5 0.04 12.5 82.14::128.73 82.68::155.09
MDM2::MAML2§ ,$ Notch signaling 0.5 0.04 12.5 76.33::76.59 77.9::78.6
MDM2::STK11§ IGF1R signaling 0.5 0.04 12.5 76.33::71.97 77.9::74.95
MDM2::STK11§ insulin receptor signaling 0.5 0.04 12.5 76.33::71.97 77.9::74.95
MDM2::TP53§ Notch signaling 0.5 0.04 12.5 76.33::128.73 77.9::155.09
AKT2::GNAS¶ Gnrh signaling 0.5 0.04 12.5 87.71::5465.46 96.84::6212.43
AKT2::GNAS¶ Calcium signaling 0.5 0.04 12.5 87.71::5465.46 96.84::6212.43
AKT2::NF2¶ Hippo signaling 0.5 0.04 12.5 87.71::85.75 96.84::87.36
AKT2::TP53¶ P53 signaling 0.5 0.04 12.5 87.71::128.73 96.84::155.09
AKT2::TP53¶ Wnt signaling 0.5 0.04 12.5 87.71::128.73 96.84::155.09
CBL::CDH1¶ RAP1 signaling 0.5 0.04 12.5 194.46::74.2 208.45::79.8













is the average GE value of all Parental conditions




is similar but with Resistant conditions, and others are likewise similar.
to drug-resistance by maintaining key cell survival and/or
proliferation signals in common down-stream pathways,
including PI3K/Akt signaling [1].
Komurov et al. [17] hypothesized that cross-talks
between EGFR/ErbB signaling and metabolic pathways
contribute to resistance to lapatinib. More specifically,
they identified that glucose deprivation reduces the
inhibiting effects of lapatinib by up-regulating con-
stituent genes and thus providing an EGFR/ErbB2-
independent mechanism of glucose uptake and cell sur-
vival [17]. Here, by using the same gene expression
datasets, we found MDM2:STK11 cross-talk between
EGFR/ErbB and IGF1R signaling, where STK11 (also
known as LKB1) phosphorylates and activates AMPK in
absence of glucose [67]. Again, in the integrated signal-
ing circuitry of pathways: p53-IGF-1-AKT-TSC2-mTOR,
a positive feedback loop (p53-PTEN AKT-MDM2-p53)
is formed which enhances p53-mediated apoptosis and
senses nutrient deprivation [67]. Thus our results com-
plement the findings of Komurov et al. by finding
signaling cross-talks between EGFR/ErbB and IGF1R
pathways.
In Netwalker analysis of our primary dataset (SKBR3
cell-line, GSE38376),we compared the expression changes
of all the samples in parental conditions (basal, 0.1 μM
and 1.0 μM) with those of all the samples in resistant
conditions (basal, 0.1 μM and 1.0 μM). However, we
conducted another experiment on both of our primary
(SKBR3 cell-line, GSE38376) and secondary datasets
(BT474 cell-line, GSE16179) in which we first identified
genes dysregulated in treatment vs basal conditions in
parental samples and then checked if those genes were
reversely changed in treatment conditions in resistant
samples. To that end, for each sample, first we calcu-
lated the fold-change(s) of parental treatment condition(s)
compared to parental basal condition, and then we cal-
culated the fold-changes of resistant basal and resistant
treatment conditions compared to parental basal condi-
tion (Additional file 1: Figure S2A and S3A). Then, we
chose only those genes for which, in any of the 3 sam-
ples, expressions were dysregulated (up-/down-regulated)
in (all the) parental treatment condition(s) (log2 of fold-
changes were positive/negative), and for that particular
sample, expressions were reversely changed (the fold-
change sign was opposite to that of parental condition)
in all the resistant treatment conditions (Additional file
1: Figure S2B and S3B). This may be a strong indicator
of sensitivity to an inhibitor in parental conditions and
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Table 3 Comparative results betweenprimary dataset (SKBR3 cell-line, GSE38376) and validationdataset (BT474
cell-line, GSE16179)
Pathway name Found in Pathway source Found in Pathway source Common cross-talks in both Studies¶
(GSE38376) (GSE16179)
Notch Signaling Reactome, Reactome, MAP2K4::NOTCH1
KEGG, KEGG,
WikiPathway WikiPathway











Insulin (IGF1R) Signaling Reactome, Reactome, MDM2::MAP2K4
WikiPathway WikiPathway TP53::MAP2K4
TGF-β Signaling Reactome, Reactome, MDM2::TFE3
WikiPathway KEGG, TP53::TFE3
WikiPathway
MAPK signaling KEGG, KEGG, MDM2::MAP2K4
WikiPathway WikiPathway
¶These common cross-talks were found using the primary dataset (104, 188 and 299 cross-talks from Reactome, KEGG and WikiPathway databases, respectively) and
validation datasets (83, 133 and 277 cross-talks from Reactome, KEGG andWikiPathway databases, respectively). Cross-talks mentioned with Bold face are those
consistent with our hypothesis that both genes in the particular cross-talk are up-regulated in resistant conditions but down-regulated in parental conditions.
the development of acquired resistance. Next, we com-
pared these selected genes to cross-talks found in results
from GSE38379 (104, 188 and 299 EGFR/ErbB cross-talks
from Reactome, KEGG and WikiPathway, respectively)
and GSE16179 (83, 133 and 277 EGFR/ErbB cross-talks
from Reactome, KEGG and WikiPathway, respectively).
Although we didn’t find any such cross-talks overlapping
with the results from the primary dataset (GSE38379),
we found 401 from our secondary dataset (GSE16179)
(Additional file 15: Table S14).
Currently, our network modeling only considers undi-
rected edges among genes. In future we would like to
generalise the approach to identify directed and indi-
rect interactions among genes. In network modeling,
a combination of both direct and indirect relation-
ships among gene-pairs was found to provide better
insights into biological systems in our previous stud-
ies [68]. The rationale for combining these two types
of gene-gene relationships in signaling networks is that
EGFR/ErbB and IGF1R can both cross-talk (EGFR/IGF1R
heterodimerization) directly at the receptor level, and
indirectly mediated by GPCR signaling, as reported
by Van der Veeken et al. [62]. Other high-throughput
datasets such as miRNA expression data, copy number
aberration data, and methylation data could also be incor-
porated into our framework to obtain a better under-
standing of gene dependencies. Note that our method-
ology exploits a fully data-driven approach for finding
putative drug-resistant cross-talks, without incorporat-
ing other prior information regarding gene-gene rela-
tionships, such as Protein-Protein Interactions. Hence,
although our data-driven approach may inherently yield
some false-positive predictions, it may also provide the
possibilities of finding novel cross-talks contributing to
drug- resistance.
Conclusions
Our proposed computational framework is able to pre-
dict putative cross-talks among signaling pathways that
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Figure 4 Heatmap of genes in putative drug-resistant cross-talks in breast cancer cell-line: BT474 (GSE16179). Heatmap image of
comparative gene expression changes of parental and resistant conditions in (A) all 78 genes in all 83, 133 and 277 putative drug-resistant
cross-talks using signaling pathways from Reactome, KEGG and WikiPathway database, respectively, and (B) 37 selected genes based on their
differential regulation. Here, for each gene, the expression value at each of the 4 conditions (2 parental conditions, and 2 resistant conditions) is the
average value of 3 sample patients [16]. For each gene, these 4 expression values (each of them is the average of 3 samples) were transformed into
z-scores (zero mean, unit standard deviation) and each z-score was normalized with the maximum absolute value of the z-scores across that
particular gene. For both (A) and (B), red and green bars indicate up-regulation and down-regulation, respectively.
play a role in drug resistance in two breast cancer
cell-lines, SKBR3 and BT474. Our framework could also
be useful for other types of cancer to enhance understand-
ing of the role of signaling cross-talks in drug resistance.
Most importantly, we believe our method can be used to
find a range of compensatory pathways that nullify/reduce
the inhibiting effects of drugs via cross-talk with targeted
pathways. These novel compensatory pathways can be
further considered as novel targets for single or combina-
tion therapies.
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Additional file 1: Appendix I. Derivation of p1-model for directed
network.
Additional file 2: Table S1. All 11,515 drug-resistant gene-pairs found in
GSE38376.
Additional file 3: Table S2. All 1,083 (841 distinct) cross-talks found
between EGFR and other 23 signaling pathways from Reactome database.
Additional file 4: Table S3. All 2,179 (1,050 distinct) cross-talks found
between ErbB and other 34 signaling pathways from KEGG database.
Additional file 5: Table S4. All 3,084 (876 distinct) cross-talks found
between ErbB and other 62 signaling pathways from WikiPathway
database.
Additional file 6: Table S5. 104 drug-resistant cross-talks found between
EGFR and other 23 signaling pathways from Reactome database
[GSE38376].
Additional file 7: Table S6. 188 drug-resistant cross-talks found between
ErbB and other 34 signaling pathways from KEGG database [GSE38376].
Additional file 8: Table S7. 299 drug-resistant cross-talks found between
ErbB and other 62 signaling pathways from WikiPathway database
[GSE38376].
Additional file 9: Table S8. 168 selected cross-talks which associated
EGFR (or ErbB) signaling pathways with 6 other signaling pathways that
were found in at least two different pathway analyses (i.e. Reactome and
KEGG, or KEGG and WikiPathway, or Reactome and WikiPathway)
[GSE38376].
Additional file 10: Table S9. All 10,811 drug-resistant gene-pairs found in
GSE16179.
Additional file 11: Table S10. 83 drug-resistant cross-talks found
between EGFR and other 23 signaling pathways from Reactome database
[GSE16179].
Additional file 12: Table S11. 133 drug-resistant cross-talks found
between ErbB and other 34 signaling pathways from KEGG database
[GSE16179].
Additional file 13: Table S12. 278 drug-resistant cross-talks found
between ErbB and other 62 signaling pathways from WikiPathway
database [GSE16179].
Additional file 14: Table S13. 86 drug-resistant cross-talks found in all
Reactome, KEGG and WikiPathway analyses where both genes in a
particular cross-talk was up-regulated in resistant conditions but
down-regulated in parental conditions [GSE16179].
Additional file 15: Table S14. 401 cross-talks from Reactome, KEGG and
WikiPathway analyses where the genes are dysregulated in parental
treatment vs parental basal condition, and reversely changed in resistant
basal + resistant treatment vs parental basal condition [GSE16179].
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